Welcome to our dedicated page for Amphenol SEC filings (Ticker: APH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amphenol鈥檚 disclosures stretch from multi-segment revenue footnotes to detailed acquisition earn-outs鈥攙aluable insights, yet hard to untangle in a hurry. If you have ever searched for the EV sensor backlog inside a 300-page report or wondered how new aerospace orders affect margins, you have felt the challenge.
Stock Titan solves this problem. Our AI reads every Amphenol quarterly earnings report 10-Q filing, annual report 10-K simplified version, and each 8-K material events explained update the moment they hit EDGAR. Interactive summaries flag where management discusses connector demand, break down goodwill from recent deals, and alert you to Amphenol insider trading Form 4 transactions鈥攜es, real-time Amphenol Form 4 insider transactions alerts on your dashboard. Need the proxy statement executive compensation tables? They are indexed alongside segment KPIs so you immediately see how pay aligns with mobile-device growth.
Whether you are tracking Amphenol executive stock transactions Form 4 before earnings, comparing wire-harness margins across periods, or simply understanding Amphenol SEC documents with AI, our platform gives you what professionals use daily: instant red-line comparisons, keyword search inside exhibits, and Amphenol earnings report filing analysis that surfaces the numbers driving guidance. All Amphenol SEC filings explained simply鈥攏o more manual downloads, just clarity.
N2OFF, Inc. (Nasdaq: NITO) has called a 2025 special meeting to seek shareholder approval for four key proposals.
- Acquisition: N2OFF will buy 100% of Israeli oncology start-up MitoCareX Bio Ltd. by issuing new NITO shares equal to 鈮�40% of post-close fully diluted shares plus up to another 25% in milestone stock, $700k cash and up to $1.6 m of future-financing proceeds. MitoCareX founders will also receive 5% RSUs and board control of the subsidiary.
- Reverse split: Board authority to effect a 1-for-2 to 1-for-150 reverse split within 12 months.
- Warrants: Approval to issue 1,850,000 common shares on exercise of a warrant held by L.I.A. Pure Capital Ltd.
- Adjournment: Standard authority if more time is needed to solicit votes.
The board unanimously recommends voting FOR all items. If approved, existing holders face substantial dilution, potential additional issuance through milestones and warrants, and the possibility of a large reverse split to maintain Nasdaq compliance. The deal adds an early-stage oncology platform but exposes N2OFF to R&D funding obligations and integration risks. Two N2OFF directors also serve on MitoCareX seller SciSparc鈥檚 board, creating related-party considerations.
FAQ
What is the current stock price of Amphenol (APH)?
What is the market cap of Amphenol (APH)?
What are the core products of Amphenol Corp?
In which industries does Amphenol operate?
How does Amphenol generate its revenue?
What is the significance of Amphenol's global presence?
How does Amphenol integrate acquisitions into its business?
How does Amphenol differentiate itself from its competitors?
What role do technological innovations play at Amphenol?
How does Amphenol serve the data communications and IT sectors?
